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1
Belmont University, Nashville, TN, 37212; 2Department of Biochemistry, Vanderbilt University,
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Neisseria gonorrhoeae has been ranked as one of five “urgent threats” for resistance by the Centers
for Disease Control and Prevention. Previously, fluoroquinolones, which target the bacterial type
II topoisomerases, gyrase and topoisomerase IV, were frontline treatments for gonorrhea.
However, clinical use of this class has been discontinued due to the prevalence of resistance
mutations in the genes encoding these enzymes. Consequently, a new class of
gyrase/topoisomerase IV-targeted agents known as Novel Bacterial Topoisomerase Inhibitors
(NBTIs) are being developed to combat this bacterial threat. Type II topoisomerases relieve
torsional stress generated in the DNA double helix during replication, transcription, and
recombination by introducing transient double-stranded breaks in DNA. Fluoroquinolones and
NBTIs stabilize these DNA breaks, thus increasing levels of DNA scission. As such, we
hypothesized that the novel NBTI, OSUAB-185, would increase levels of DNA cleavage mediated
by N. gonorrhoeae type II topoisomerases. Using in vitro DNA cleavage assays, we determined
that OSUAB-185 increases levels of single-stranded DNA cleavage mediated by N. gonorrhoeae
gyrase and topoisomerase IV. Whereas double-stranded breaks mediated by N. gonorrhoeae
gyrase were suppressed, matching previously reported topoisosomerase-NBTI interactions,
double-stranded breaks mediated by topoisomerase IV were enhanced. Given its unique ability to
increase levels of double stranded breaks, we focused our studies on the activity of OSUAB-185
against topoisomerase IV. Results indicate that at 10 µM OSUAB-185, the DNA cleavage/ligation
equilibrium is reached by 10 minutes. Additional experiments confirm that NBTI-induced DNA
cleavage enhancement is mediated by N. gonorrhoeae topoisomerase IV. Thus, this NBTI shows
promise as a new antibacterial to effectively target N. gonorrhoeae. Future studies will monitor
the activity of OSUAB-185 against fluoroquinolone- and NBTI-resistant N. gonorrhoeae type II
enzymes, which supports our long-term goal of designing new drugs to overcome fluoroquinolone
resistant infections.

